Future perspectives on the treatment of hepatocellular carcinoma with cisplatin

Table 3 Transcatheter arterial chemoembolization (inc. transcatheter arterial infusion with lipiodol)

Author	Country	Publicationyear	Treatment schedule	Root	n	RR (%)	MST (M)	1yrs (%)	2yrs (%)	3yrs (%)	5yrs (%)
Ikeda et al[40]	Japan	1992	DXR/Lip 10.5 mg1	Lip-TAI	76	23.7	-	68.0	41.0	24.0	-
			MMC/Lip 7.8 mg1 Lip 3.7 mL1
			CDDP 135.7 mg1
Yodono et al[41]	Japan	1992	CDDP 20 mg/sq, d1-5	TAI	14	46.2	27.6	50.0	43.0	34.0	-
			ETP 30-40 mg/sq, d1-5	+Lip-TACE
			5-FU 250 mg/body, d1-26 + CDDP/Lip + GS
			CDDP 50 mg/sq, d2,8	TAI	31	48.4	21.7	77.0	42.0	-	-
			ETP 50-60 mg/sq, d4-6	+Lip-TACE
			DXR 20 mg/sq, d1,7 + CDDP/Lip + GS
Hatanaka et al[42]	Japan	1995	CDDP 50-100 mg	TACE	60	-	-	80.4	65.2	48.6	-
			DXR 20-40 mg
			FUDR 3-5 g + GS
			CDDP 50-100 mg	Lip-TACE	78	-	-	86.3	55.3	34.8	-
			DXR 20-40 mg Lip 4.8 mL1
			FUDR 3-5 g + GS
			CDDP 50-100 mg	Lip-TAI	159	-	-	65.9	50.3	36.2	-
			DXR 20-40 mg Lip 4.9 mL1
			FUDR 3-5 g
Raoul et al[43]	France	1997	CDDP 70 mg (saline 140 mL)/Lip 10 mL + GS	Lip-TACE	64	57.0	-	42.2	22.1	2.8	-
Carr[20]	USA	2002	CDDP 125-200 mg/sq q4-8w + GS	TACE	31	58.1	30.7	-	-	-	-
Shibata et al[44]	Japan	1989	CDDP 20-150 mg (CDDP/Lip: 20 mg/mL)	Lip-TAI	71	46.5	-	55.0	-	-	-
Kawakami et al[45]	Japan	1993	CDDP 50 mg (CDDP/Lip: 10 mg/mL)	Lip-TAI	12	12.5	7.0	-	-	-	-
			CDDP 50 mg (CDDP/Lip: 10 mg/mL) + GS	Lip-TACE	30	45.5	25	81.3	56.8	-	-
Ono et al[46]	Japan	2000	CDDP 50 mg1 (CDDP/Lip: 10 mg/mL) + GS	Lip-TACE	38	45.0	-	-	49.0	-	19.0
			DXR 43 mg1 (20-50 mg)/Lip + GS	Lip-TACE	46	38.0	-	-	31.0	-	6.0
Kamada et al[47]	Japan	2001	CDDP 41 mg1 (15-70 mg)/Lip + GS	Lip-TACE	108	15.0	24.0	81.0	-	41.0	19.0
			(CDDP/Lip: 10 mg/mL)	or Lip-TAI
			DXR 57mg1 (20-100 mg)/Lip + GS	Lip-TACE or Lip-TAI	26	4.0	17.0	67.0	-	18.0	0.0
Maeda et al[48]	Japan	2003	CDDP 70.5 mg1/Lip	Lip-TAI	143	57.3	-	89.2	65.3	48.8	29.6
			(CDDP/Lip: 20 mg/mL)
			CDDP 78.4 mg1/Lip + GS	Lip-TACE	96	62.5	-	85.2	67.0	48.7	24.2
			(CDDP/Lip: 20 mg/mL)
Ikeda et al[5,6]	Japan	2009	CDDP 50 mg1 (20-150 mg)/Lip	Lip-TAI	94	51.1	30.0	81.6	65.2	39.8	18.3
		-2004	(CDDP/Lip: 20 mg/mL)
			CDDP 70 mg1 (30-150 mg)/Lip + GS	Lip-TACE	74	73.0	37.2	87.8	-	52.2	25.0
			(CDDP/Lip: 20mg/mL)
Uyama et al[49]	Japan	2008	CDDP80 mg1 /Lip (40-100mg) + GS	Lip-TACE	24	45.8	-	-	-	-	-
			(CDDP/Lip: 20 mg/mL)
Yamashita et al[50]	Japan	2009	CDDP 35 mg/sq	Lip-TAI	35	57.1	-	-	-	-	-
			(CDDP/Lip: 10-20 mg/mL)

CDDP: Cisplatin, DXR: Doxorubicin; EPI: Epirubicin; ETP: Etoposide; 5-FU: 5-fluorouracil; FUDR: Floxuridine; MMC: Mitomycin C; GS: Gelatin sponge; Lip: Lipiodol; TAI: Trasctheter arterial infusion; TACE: Trasctheter arterial chemoembolization; RR: Response rate; MST: Median survival time; 1yrs: 1 year survival rate.

¹Mean.